For VIP in-vivo testing on human cells show VIP leads to weakened binding of chemokines to CCR5. Testing showed 75% reduction for CCL5 (RANTES). Personally I like the 100% non-binding of leronlimab. But VIP may be a good substitute until Cytodyn ramps up production.
I ran across OB-002 last year. I have seen no evidence that OB-002 preferentially binds to CCR5. Being competitive its effect would depend on the percentage of OB-002 to CCL5 (RANTES).